体外膜氧合支持呼吸衰竭患者生存率改善:韩国多中心回顾性研究
该研究为韩国16家医院参与的多中心回顾性研究,纳入2012–2015年因急性呼吸衰竭接受ECMO的连续患者。共分析487例(占同期16家医院ECMO患者的19.7%),呼吸衰竭ECMO例数从104例增至153例,院内生存率从30.8%升至35.9%。俯卧位通气使用率从6.8%升至49.0%(p<0.001),神经肌肉阻滞剂使用率从28.2%升至58.2%(p<0.001)。多因素回归显示高龄、使用皮质类固醇、连续性肾脏替代治疗、驱动压升高和ECMO持续时间延长与死亡率增加相关。
要点
- 韩国16家医院2012–2015年因呼吸衰竭接受ECMO的487例患者中,院内生存率从30.8%升至35.9%。
- 呼吸衰竭ECMO例数从104例增至153例,同期俯卧位通气使用率从6.8%升至49.0%(p<0.001)。
- 神经肌肉阻滞剂使用率从28.2%升至58.2%(p<0.001)。
- 多因素回归显示与死亡率增加相关的因素:高龄(OR 1.038,95%CI 1.022–1.054)、使用皮质类固醇(OR 2.251,95%CI 1.153–4.397)、连续性肾脏替代治疗(OR 2.196,95%CI 1.135–4.247)、驱动压(OR 1.072,95%CI 1.031–1.114)、ECMO持续时间延长(OR 1.020,95%CI 1.003–1.038)。
适用人群与场景
- 2012–2015年韩国16家医院因急性呼吸衰竭接受ECMO的连续患者,共分析487例(占同期16家医院ECMO患者的19.7%)。
研究设计与关键结果
- 研究类型:多中心回顾性研究;样本量:16家医院共2472例接受ECMO,其中因呼吸衰竭接受ECMO并分析487例(19.7%);韩国全国同期5552例接受ECMO。
- 呼吸衰竭ECMO例数从104例增至153例,院内生存率从30.8%升至35.9%。
- 俯卧位通气使用率从6.8%升至49.0%(p<0.001),神经肌肉阻滞剂使用率从28.2%升至58.2%(p<0.001)。
- 多因素回归显示与死亡率增加相关的因素:高龄(OR 1.038,95%CI 1.022–1.054)、使用皮质类固醇(OR 2.251,95%CI 1.153–4.397)、连续性肾脏替代治疗(OR 2.196,95%CI 1.135–4.247)、驱动压(OR 1.072,95%CI 1.031–1.114)、ECMO持续时间延长(OR 1.020,95%CI 1.003–1.038)。
证据类型、等级与局限
- 证据类型:多中心回顾性研究;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究显示2012–2015年韩国因呼吸衰竭接受ECMO的患者数量增加,院内生存率从30.8%升至35.9%,同期ECMO前俯卧位通气和神经肌肉阻滞剂使用增加。
- 多因素回归显示高龄、使用皮质类固醇、连续性肾脏替代治疗、驱动压升高和ECMO持续时间延长与死亡率增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although the utilization of extracorporeal membrane oxygenation (ECMO) is increasing and its technology is evolving, only a few epidemiologic reports have described the uses and outcomes of ECMO. The aim of this study was to investigate the changes in utilization and survival rate in patients supported with ECMO for severe respiratory failure in Korea.
METHODS: This was a multicenter study on consecutive patients who underwent ECMO across 16 hospitals in Korea. The records of all patients who required ECMO for acute respiratory failure between 2012 and 2015 were retrospectively reviewed, and the utilization of ECMO was analyzed over time.
RESULTS: During the study period, 5552 patients received ECMO in Korea as a whole, and a total of 2472 patients received ECMO at the participating 16 hospitals. We analyzed 487 (19.7%) patients who received ECMO for respiratory failure. The number of ECMO procedures provided for respiratory failure increased from 104 to 153 during the study period. The in-hospital survival rate increased from 30.8% to 35.9%. The use of prone positioning increased from 6.8% to 49.0% (p < 0.001), and the use of neuromuscular blockers also increased from 28.2% to 58.2% (p < 0.001). Multiple regression analysis showed that old age (OR 1.038 (95% CI 1.022, 1.054)), use of corticosteroid (OR 2.251 (95% CI 1.153, 4.397)), continuous renal replacement therapy (OR 2.196 (95% CI 1.135, 4.247)), driving pressure (OR 1.072 (95% CI 1.031, 1.114)), and prolonged ECMO duration (OR 1.020 (95% CI 1.003, 1.038)) were associated with increased odds of mortality.
CONCLUSIONS: Utilization of ECMO and survival rates of patients who received ECMO for respiratory failure increased over time in Korea. The use of pre-ECMO prone positioning and neuromuscular blockers also increased during the same period.
参考来源
- Baek MS, Lee SM, Chung CR, et al. Improvement in the survival rates of extracorporeal membrane oxygenation-supported respiratory failure patients: a multicenter retrospective study in Korean patients. Crit Care. 2019. PMID: 30606235. doi:10.1186/s13054-018-2293-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。